Enlivex Therapeutics Ltd. (ENLV) Statistics & Valuation Metrics - Stocknear

Enlivex Therapeutics Ltd.

NASDAQ: ENLV · Real-Time Price · USD
1.06
-0.01 (-0.93%)
At close: Sep 05, 2025, 3:59 PM
1.06
0.00%
After-hours: Sep 05, 2025, 07:34 PM EDT

Enlivex Therapeutics Statistics

Share Statistics

Enlivex Therapeutics has 23.85M shares outstanding. The number of shares has increased by 11.42% in one year.

23.85M
11.42%
8.46%
14.49%
22.66M
2,453
0.46%

Short Selling Information

The latest short interest is 51.75K, so 0.24% of the outstanding shares have been sold short.

51.75K
0.24%
0.26%
1

Valuation Ratios

The PE ratio is -1.6 and the forward PE ratio is -1.81. Enlivex Therapeutics's PEG ratio is 0.03.

-1.6
-1.81
0
n/a
1.02
-1.83
0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Enlivex Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.02.

6.84
6.84
0.02
-0.04
-0.04
-1195.08

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-211.46K
71
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -16.54% in the last 52 weeks. The beta is 0.83, so Enlivex Therapeutics's price volatility has been higher than the market average.

0.83
-16.54%
1.25
1.11
40.77
535,011

Income Statement

n/a
-545K
-15.54M
-15.01M
-14.47M
-15.01M
-0.73
Full Income Statement

Balance Sheet

The company has 3.3M in cash and 534K in debt, giving a net cash position of 2.77M.

3.3M
534K
2.77M
-127.11M
22.6M
18M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.01M and capital expenditures -103K, giving a free cash flow of -13.11M.

-13.01M
-103K
-13.11M
-0.64
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

ENLV does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for ENLV is $13, which is 1126.4% higher than the current price. The consensus rating is "Buy".

$13
1126.4%
Buy
2
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Stock Splits

The last stock split was on Mar 6, 2019. It was a backward split with a ratio of 1:8.

Mar 6, 2019
backward
1:8

Scores

-5.14
1